Last Update: Jul 16, 2026
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform
ClinicalTrials.gov Identifier:
Novartis Reference Number:CAAA617A0US04
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Prostatic Neoplasms, Castration-Resistant
Recruiting
17111
Jun 30, 2026
Nov 30, 2026
Male
18 Years - 115 Years (Adult, Older Adult)
Eligibility Criteria
Inclusion criteria:
* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
* Male sex at index, where index is the date of initial mCRPC diagnosis.
* Age 18 years at index.
Exclusion criteria:
• None
Novartis
Recruiting
East Hanover,New Jersey,07936,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.